CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Eptinezumab

Eptinezumab

In February 2020, Vyepti (eptinezumab) became the first quarterly infusion of a CGRP monoclonal antibody to be approved for the prevention of migraine in adults. Approval was supported by data including the results of a large Phase 2b dose-ranging study in patients with chronic migraine and two Phase 3 trials – PROMISE 1 in episodic migraine and PROMISE 2 in chronic migraine.


Download slideset »


« back to Slides